- Home
- TPST vs AIMD Comparison
TPST vs AIMD Comparison
Compare TPST & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | AIMD |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 9.8M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | AIMD |
|---|---|---|
| Price | $2.16 | $1.45 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 53.4K | 31.1K |
| Earning Date | 03-24-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.44 |
| 52 Week High | $12.22 | $4.50 |
Technical Indicators
Market Signals| Indicator | TPST | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 46.15 |
| Support Level | $2.14 | $1.31 |
| Resistance Level | $2.49 | $1.73 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 29.07 | 46.88 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.